{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:32:37Z","timestamp":1791253957141,"version":"4.1.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Blockade of the CD47\/SIRPa axis has emerged as a promising approach to enhance macrophage-mediated anti-tumor activities in cancer immunotherapy. However, the clinical application of early CD47 antibodies has been associated with significant hematotoxicities, including hemagglutination, anemia, and thrombopenia. Although several CD47 antibodies have generally avoided hemagglutination, anemia, and thrombopenia remain, potentially mediated by enhanced phagocytosis of erythrocytes and thrombocytes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      1B2\u201310 is a humanized CD47-neutralizing antibody generated by mouse immunization and phage display technology. Its efficacy and safety were evaluated using\n                      <jats:italic>in vitro<\/jats:italic>\n                      assays, tumor xenograft models, and studies in cynomolgus monkeys.\n                      <jats:italic>In silico<\/jats:italic>\n                      modeling and mutagenesis analyses were performed to identify the 1B2-10 binding epitopes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:italic>In vitro<\/jats:italic>\n                      , 1B2\u201310 exhibited minimized binding to erythrocytes and thrombocytes, did not induce hemagglutination, and reduced erythrocyte phagocytosis. It enhanced macrophage-mediated phagocytosis of tumor cells and showed potent antitumor effects as a monotherapy or in combination with a PD-1 antibody in tumor models. In cynomolgus monkeys, single doses of 1B2\u201310 at 120 mg\/kg and repeated doses at 100 mg\/kg were well-tolerated, with no significant hematological toxicities observed.\n                      <jats:italic>In silico<\/jats:italic>\n                      studies revealed the molecular basis for reduced erythrocyte binding, demonstrating that two critical N-linked glycans sterically masked epitopes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These findings suggest that 1B2-10 demonstrates a favorable efficacy and safety profile, indicating great therapeutic potential for cancer. Based on these studies, 1B2\u201310 has been renamed as DS003 and is currently advancing through Phase I clinical trials in China to further evaluate its safety profile and preliminary efficacy in human subjects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1686180","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T13:36:57Z","timestamp":1764164217000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["A CD47 antibody with minimized erythrocyte and thrombocyte toxicities"],"prefix":"10.3389","volume":"15","author":[{"given":"Min","family":"Pei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Dong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Fan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai-Yi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Feng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Jian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Di","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan-Huan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Ling","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Ru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01056-8","article-title":"Next generation of immune checkpoint inhibitors and beyond","volume":"14","author":"Marin-Acevedo","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2991\/jegh.k.191008.001","article-title":"Current cancer epidemiology","volume":"9","author":"Mattiuzzi","year":"2019","journal-title":"J Epidemiol Glob Health"},{"key":"B3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-022-01325-0","article-title":"Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts","volume":"15","author":"Wang","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3931","article-title":"CD47 blockade triggers T cell-mediated destruction of immunogenic tumors","volume":"21","author":"Liu","year":"2015","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40364-022-00373-5","article-title":"Targeting CD47\/SIRP\u03b1 as a therapeutic strategy, where we are and where we are headed","volume":"10","author":"Qu","year":"2022","journal-title":"biomark Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0183-z","article-title":"Phagocytosis checkpoints as new targets for cancer immunotherapy","volume":"19","author":"Feng","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41392-023-01365-z","article-title":"Emerging phagocytosis checkpoints in cancer immunotherapy","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.757480","article-title":"CD47 as a promising therapeutic target in oncology","volume":"13","author":"Hai","year":"2022","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14081930","article-title":"CD47-SIRP\u03b1 Checkpoint disruption in metastases requires tumor-targeting antibody for molecular and engineered macrophage therapies","volume":"14","author":"Andrechak","year":"2022","journal-title":"Cancers"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2017.12.005","article-title":"SIRP\u03b1\u2013CD47 immune checkpoint blockade in anticancer therapy","volume":"39","author":"Veillette","year":"2018","journal-title":"Trends Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1305569110","article-title":"Anti-CD47 antibody\u2013mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response","volume":"110","author":"Tseng","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1106550108","article-title":"CD47-signal regulatory protein-\u03b1 (SIRP\u03b1) interactions form a barrier for antibody-mediated tumor cell destruction","volume":"108","author":"Zhao","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1604268113","article-title":"Durable antitumor responses to CD47 blockade require adaptive immune stimulation","volume":"113","author":"Sockolosky","year":"2016","journal-title":"Proc Natl Acad Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1348852","article-title":"Opportunities and challenges for anti-CD47 antibodies in hematological Malignancies","volume":"15","author":"Xu","year":"2024","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1378647","article-title":"Targeting the CD47\/SIRP\u03b1 pathway in Malig-nancies: recent progress, difficulties and future perspectives","volume":"14","author":"Jiang","year":"2024","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1121623109","article-title":"The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors","volume":"109","author":"Willingham","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1105270108","article-title":"Binding of blood proteins to carbon nanotubes reduces cytotoxicity","volume":"108","author":"Ge","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02018","article-title":"First-in-human, first-in-class phase I trial of the anti-CD47 antibody hu5F9-G4 in patients with advanced cancers","volume":"37","author":"Sikic","year":"2019","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.7009","article-title":"The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results","volume":"37","author":"Sallman","year":"2019","journal-title":"JCO"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7020","article-title":"Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results","volume":"40","author":"Daver","year":"2022","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e005517","DOI":"10.1136\/jitc-2022-005517","article-title":"Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity","volume":"10","author":"Qu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e000413","DOI":"10.1136\/jitc-2019-000413","article-title":"The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a","volume":"8","author":"Peluso","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.2630","article-title":"Safety of AK117, an anti-CD47 mAb, in patients with advanced or metastatic solid tumors in a phase I study","volume":"39","author":"Gan","year":"2021","journal-title":"JCO"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-1079","article-title":"Development of AO-176, a next-generation humanized anti-CD47 antibody with novel anticancer properties and negligible red blood cell binding","volume":"19","author":"Puro","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1182\/blood-2018-99-118456","article-title":"Therapeutic potential of AO-176, a next generation humanized CD47 antibody, for hematologic Malignancies","volume":"132","author":"Wilson","year":"2018","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.2516","article-title":"A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors","volume":"39","author":"Burris","year":"2021","journal-title":"JCO"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1182\/blood-2019-122793","article-title":"TJC4, a differentiated anti-CD47 antibody with novel epitope and RBC sparing properties","volume":"134","author":"Meng","year":"2019","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-SITC2020.0385","article-title":"385 A first-in-human study of lemzoparlimab, a differentiated anti-CD47 antibody, in subjects with relapsed\/refractory Malignancy: initial monotherapy results","volume":"8","author":"Berlin","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"S827","DOI":"10.1016\/j.annonc.2022.07.743","article-title":"617O Lemzoparlimab, a differentiated anti-CD47 mAb, in combination with azacitidine (AZA) in patients with newly diagnosed higher risk myelodysplastic syndrome (HR-MDS): Initial clinical results","volume":"33","author":"Xiao","year":"2022","journal-title":"Ann Oncol"},{"key":"B30","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-1-61779-974-7_3","article-title":"Cloning single-chain antibody fragments (ScFv) from hyrbidoma cells","volume-title":"Antibody engineering: methods and protocols","author":"Toleikis","year":"2012"},{"key":"B31","article-title":"Tailoring kinetics of antibodies using focused combinatorial libraries","volume-title":"Recombinant antibodies for cancer therapy: methods and protocols","author":"Wu","year":"2003"},{"key":"B32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ymeth.2005.01.0-05","article-title":"Antibody humanization by framework shuffling","volume":"36","author":"Dall'Acqua","year":"2005","journal-title":"Methods"},{"key":"B33","first-page":"197","article-title":"Simultaneous humanization and affinity optimization of monoclonal antibodies","volume-title":"Recombinant antibodies for cancer therapy: methods and Protocols","author":"Wu","year":"2003"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1395854","article-title":"Comparison of \u201cframework Shuffling\u201d and \u201cCDR Grafting\u201d in humanization of a PD-1 murine antibody","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41-586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1186\/s12859-018-2414-9","article-title":"Distinguishing crystallographic from biological interfaces in protein complexes: role of intermolecular contacts and energetics for classification","volume":"19","author":"Elez","year":"2018","journal-title":"BMC Bioinf"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btz437","article-title":"PRODIGY-crystal: a web-tool for classification of biological interfaces in protein complexes","volume":"35","author":"Jim\u00e9nez-Garc\u00eda","year":"2019","journal-title":"Bioinformatics"},{"key":"B38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41392-020-0121-2","article-title":"The identification of a CD47-blocking \u201chotspot\u201d and design of a CD47\/PD-L1 dual-specific antibody with limited hemagglutination","volume":"5","author":"Shi","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109587","article-title":"Antibody: CD47 ratio regulates macrophage phagocytosis through competitive receptor phosphorylation","volume":"36","author":"Suter","year":"2021","journal-title":"Cell Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1424907112","article-title":"Macrophages eat cancer cells using their own calreticulin as a guide: Roles of TLR and Btk","volume":"112","author":"Feng","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.2517","article-title":"First-in-human phase 1 dose escalation study of HX-009, a novel recombinant humanized anti-PD-1 and CD47 bispecific antibody, in patients with advanced Malignancies","volume":"39","author":"Roohullah","year":"2021","journal-title":"JCO"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-CT513","article-title":"Abstract CT513: Phase I study of IBI322 (anti-CD47\/PD-L1 bispecific antibody) monotherapy therapy in patients with advanced solid tumors in China","volume":"82","author":"Wang","year":"2022","journal-title":"Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1182\/blood-2021-145584","article-title":"A phase 2, open-label, multiarm, multicenter study to evaluate magrolimab combined with antileukemia therapies for first-line, relapsed\/refractory, or maintenance treatment of acute myeloid leukemia","volume":"138","author":"Vyas","year":"2021","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"6705","DOI":"10.1182\/blood-2024-200541","article-title":"Trial in progress: A randomized, double-blind, placebo-controlled, multicenter phase 2 study of AK117\/placebo in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes (AK117-205)","volume":"144","author":"Zeidan","year":"2024","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/abt\/tbaa006","article-title":"Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRP\u03b1 structure\u2013function","volume":"3","author":"Jalil","year":"2020","journal-title":"Antib Ther"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.4_suppl.114","article-title":"A phase Ib\/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients","volume":"38","author":"Fisher","year":"2020","journal-title":"JCO"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07443-8","article-title":"Engineered CD47 protects T cells for enhanced antitumour immunity","volume":"630","author":"Yamada-Hunter","year":"2024","journal-title":"Nature"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2860","article-title":"The advances in targeting CD47\/SIRP\u03b1 \u201cdo not eat me\u201d axis and their ongoing challenges as an anticancer therapy","volume":"15","author":"Gracia-Hernandez","year":"2024","journal-title":"Oncotarget"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1686180\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T13:36:58Z","timestamp":1764164218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1686180\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":48,"alternative-id":["10.3389\/fonc.2025.1686180"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1686180","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"article-number":"1686180"}}